Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

  • Post published:March 2, 2022
  • Post category:Press Release
Read more about the article Red Light Holland Reports Fiscal Third Quarter Results

Red Light Holland Reports Fiscal Third Quarter Results

  • Post published:March 1, 2022
  • Post category:Press Release
Read more about the article Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

  • Post published:March 1, 2022
  • Post category:Press Release
Read more about the article Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

  • Post published:February 28, 2022
  • Post category:Press Release
Read more about the article Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

  • Post published:February 28, 2022
  • Post category:Psychedelic Bulletin
Read more about the article HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

  • Post published:February 24, 2022
  • Post category:Press Release
Read more about the article Entheon Biomedical Announces EBIQ-101 First-Patient Dose

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

  • Post published:February 24, 2022
  • Post category:Press Release
Read more about the article Lobe Sciences Ltd. Strengthens Its Balance Sheet

Lobe Sciences Ltd. Strengthens Its Balance Sheet

  • Post published:February 24, 2022
  • Post category:Press Release
Read more about the article COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

  • Post published:February 24, 2022
  • Post category:Press Release
Read more about the article MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

  • Post published:February 23, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More